Innovation Signals

Biology as software: the AI + synthetic biology inflection, and four signals to watch

AI and synthetic biology are converging to make biological R&D programmable — compressing timelines from years to weeks and opening whitespace across pharma, chemicals, food, and environmental services. This inaugural issue analyzes the inflection point in depth, then covers four supporting signals: biofoundry infrastructure growth, quantum sensing entering its commercial phase, the cell agriculture cost problem becoming solvable, and epigenetics shifting from research tool to drug platform.